CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1 G93A mice with a C57BL/6 background
Abstract The synthetic copper-containing compound, CuATSM, has emerged as one of the most promising drug candidates developed for the treatment of amyotrophic lateral sclerosis (ALS). Multiple studies have reported CuATSM treatment provides therapeutic efficacy in various mouse models of ALS without...
Main Authors: | Jeremy S. Lum, Mikayla L. Brown, Natalie E. Farrawell, Luke McAlary, Diane Ly, Christen G. Chisholm, Josh Snow, Kara L. Vine, Tim Karl, Fabian Kreilaus, Lachlan E. McInnes, Sara Nikseresht, Paul S. Donnelly, Peter J. Crouch, Justin J. Yerbury |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-98317-w |
Similar Items
-
Imaging of hypoxia using CuATSM
by: Hueting, R, et al.
Published: (2013) -
Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SODG93A mice co-expressing the Copper-Chaperone-for-SOD
by: Jared R. Williams, et al.
Published: (2016-05-01) -
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
by: Fernando G. Vieira, et al.
Published: (2017-06-01) -
Strategies to promote the maturation of ALS-associated SOD1 mutants: small molecules return to the fold
by: Luke McAlary, et al.
Published: (2019-01-01) -
Propensity of mutant SOD1 to form a destabilized monomer predicts cellular aggregation and toxicity but not in vitro aggregation propensity
by: Luke McAlary, et al.
Published: (2016-11-01)